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A bs tr ac t
Background
In observational analyses, higher levels of high-density lipoprotein (HDL) choles-
terol have been associated with a lower risk of coronary heart disease events. How-
ever, whether raising HDL cholesterol levels therapeutically reduces cardiovascular 
risk remains uncertain. Inhibition of cholesteryl ester transfer protein (CETP) rais-
es HDL cholesterol levels and might therefore improve cardiovascular outcomes.
Methods
We randomly assigned 15,871 patients who had had a recent acute coronary syn-
drome to receive the CETP inhibitor dalcetrapib, at a dose of 600 mg daily, or placebo, 
in addition to the best available evidence-based care. The primary efficacy end point 
was a composite of death from coronary heart disease, nonfatal myocardial infarc-
tion, ischemic stroke, unstable angina, or cardiac arrest with resuscitation.
Results
At the time of randomization, the mean HDL cholesterol level was 42 mg per deci-
liter (1.1 mmol per liter), and the mean low-density lipoprotein (LDL) cholesterol 
level was 76 mg per deciliter (2.0 mmol per liter). Over the course of the trial, HDL 
cholesterol levels increased from baseline by 4 to 11% in the placebo group and by 
31 to 40% in the dalcetrapib group. Dalcetrapib had a minimal effect on LDL cho-
lesterol levels. Patients were followed for a median of 31 months. At a prespecified 
interim analysis that included 1135 primary end-point events (71% of the projected 
total number), the independent data and safety monitoring board recommended 
termination of the trial for futility. As compared with placebo, dalcetrapib did not 
alter the risk of the primary end point (cumulative event rate, 8.0% and 8.3%, re-
spectively; hazard ratio with dalcetrapib, 1.04; 95% confidence interval, 0.93 to 
1.16; P = 0.52) and did not have a significant effect on any component of the pri-
mary end point or total mortality. The median C-reactive protein level was 0.2 mg 
per liter higher and the mean systolic blood pressure was 0.6 mm Hg higher with 
dalcetrapib as compared with placebo (P<0.001 for both comparisons).
Conclusions
In patients who had had a recent acute coronary syndrome, dalcetrapib increased 
HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events. 
(Funded by F. Hoffmann–La Roche; dal-OUTCOMES ClinicalTrials.gov number, 
NCT00658515.)
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High-density lipoproteins (HDLs) participate in the process of cellular cho-lesterol efflux and may have additional 
protective effects against atherothrombosis.1 An 
inverse association between levels of HDL cho-
lesterol and incident events of coronary heart dis-
ease has been shown in observational studies2,3 
and persists in most post hoc analyses and meta-
analyses of trials of statin therapy for patients 
with cardiovascular risk factors, chronic cardio-
vascular disease, or recent acute coronary syn-
drome.4-10 However, it remains uncertain wheth-
er pharmacologic intervention that raises HDL 
cholesterol levels results in decreased cardiovas-
cular risk.11-16 Moreover, changes in HDL choles-
terol levels may not reflect changes in the physi-
ologic functions of HDLs.17
Cholesteryl ester transfer protein (CETP) me-
diates the transfer of cholesteryl ester from 
HDLs to atherogenic lipoprotein particles con-
taining apolipoprotein B, such as low-density 
lipoprotein (LDL). In most,18-20 but not all,21 
analyses, genetic polymorphisms resulting in a 
lower mass or activity of CETP are associated 
with higher HDL cholesterol levels, lower LDL 
cholesterol levels, and a lower risk of coronary 
heart disease. These observations have led to the 
development of CETP inhibitors as drugs that 
might reduce cardiovascular risk.
Torcetrapib, the first CETP inhibitor to be 
evaluated in a phase 3 clinical trial,22 increased 
HDL cholesterol levels by more than 70% and 
decreased LDL cholesterol levels by 25% but 
caused excess morbidity and mortality associat-
ed with elevation of aldosterone levels and blood 
pressure. Dalcetrapib is a CETP inhibitor that 
raised HDL cholesterol levels by approximately 
30% in phase 2 studies, without significant ef-
fects on LDL cholesterol levels, blood pressure, 
or circulating neurohormones.23,24 We designed 
a phase 3 trial, the dal-OUTCOMES study, to 
evaluate the effects of dalcetrapib on cardiovas-
cular risk among patients with a recent acute 
coronary syndrome.
Me thods
Study Oversight
The protocol, which is available with the full text 
of this article at NEJM.org, was conceived by 
members of the independent academic executive 
steering committee, developed by that commit-
tee in conjunction with the sponsor (F. Hoff-
mann–La Roche), and approved by the responsi-
ble regulatory agencies and ethics committees. 
Quintiles (a clinical research organization), Mon-
treal Heart Institute Coordinating Center, and 
Cleveland Clinic Coordinating Center for Clinical 
Research managed the study and collected the 
data. An independent data and safety monitoring 
board monitored the trial and performed analy-
ses of unblinded data. The analyses reported in 
this article were performed by two of the authors 
who are employees of the sponsor and were inde-
pendently confirmed by the academic statistician 
on the executive steering committee. All drafts of 
the manuscript were written by the first author 
with input from all the authors. The members of 
the executive steering committee made the deci-
sion to submit the manuscript for publication 
and assume responsibility for the completeness 
and accuracy of the data and for the fidelity of 
the study to the protocol.
Study Population
Details of the study design have been published 
previously.25 Patients 45 years of age or older who 
provided written informed consent were eligible 
to participate if they had been hospitalized for an 
acute coronary syndrome characterized by elevat-
ed cardiac biomarkers, with symptoms of acute 
myocardial ischemia, ischemic electrocardio-
graphic abnormalities that were new or pre-
sumed to be new, or loss of viable myocardium 
on imaging. Patients without elevated cardiac 
biomarkers were eligible to participate if symp-
toms of acute myocardial ischemia were accom-
panied by electrocardiographic changes that 
were new or presumed to be new and by addi-
tional evidence of obstructive coronary disease.25 
Patients who had a myocardial infarction associ-
ated with percutaneous coronary intervention 
were also eligible.25 All patients had to be follow-
ing individualized, evidence-based programs for 
lowering their LDL cholesterol levels by means of 
statin therapy (if they did not have unacceptable 
side effects) and diet, with a target LDL choles-
terol level of 100 mg per deciliter (2.6 mmol per 
liter) or lower and preferably 70 mg per deciliter 
(1.8 mmol per liter) or lower. However, no spe-
cific statin agent or dose was specified, and pa-
tients were not excluded if the LDL cholesterol 
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level remained above 100 mg per deciliter. There 
were no exclusions on the basis of the HDL cho-
lesterol level; however, patients with serum tri-
glyceride levels of 400 mg per deciliter (4.5 mmol 
per liter) or higher were excluded. Other exclu-
sion criteria are listed in the Supplementary Ap-
pendix, available at NEJM.org.
Study Procedures
We entered patients who met the inclusion crite-
ria into a single-blind, placebo run-in period to 
assess adherence, ensure that no exclusion crite-
ria were met, and allow time for metabolic steady 
state to be achieved after the index acute coro-
nary event. After 4 to 12 weeks of run-in, and no 
later than 12 weeks after the index event, qualify-
ing patients were randomly assigned, in a 1:1 ra-
tio, to receive dalcetrapib at a dose of 600 mg 
daily or matching placebo, with randomization 
stratified according to country and status with 
respect to cardiac biomarker levels (elevated or 
not elevated) at the time of the index event.
Study End Points
The primary efficacy end point was a composite 
of death from coronary heart disease, a major 
nonfatal coronary event (myocardial infarction, 
hospitalization for unstable angina with objec-
tive evidence of acute myocardial ischemia, or 
cardiac arrest with resuscitation), or ischemic 
stroke. Secondary efficacy end points included 
each component of the primary composite end 
point, unanticipated coronary revascularization 
(not including revascularization for restenosis at 
the previous intervention site), death from any 
cause, and changes in levels of circulating lipo-
proteins and inflammatory markers.
Statistical Analysis
The primary efficacy analysis, which was per-
formed according to the intention-to-treat prin-
ciple, was based on the time to the first occur-
rence of any component of the primary composite 
end point in any patient from the time of ran-
domization to the termination of the trial. We 
projected that with 1600 primary end-point 
events, the study would have 90% power to detect 
a 15% reduction in the relative risk of an event 
with dalcetrapib as compared with placebo, as-
suming an average baseline HDL cholesterol level 
of 40 mg per deciliter (1.0 mmol per liter) and an 
increase of approximately 11 mg per deciliter (0.3 
mmol per liter) with dalcetrapib. Two interim 
analyses, including an analysis for futility, were 
to be performed after approximately 800 and 
1120 primary end-point events had occurred. Es-
timates of hazard ratios and 95% confidence in-
tervals for comparisons of dalcetrapib with pla-
cebo were calculated with the use of Cox 
proportional-hazards models stratified accord-
ing to region and type of index event. Event rates 
are presented as 3-year Kaplan–Meier estimates. 
Continuous data are presented as means and 
standard deviations, unless otherwise indicated. 
Additional analytic methods are described in the 
Supplementary Appendix.
R esult s
Patients
From April 2008 through July 2010, a total of 
15,871 patients were enrolled at 935 sites in 27 
countries and were included in the intention-to-
treat population; 87% of the patients had elevat-
ed cardiac biomarkers at the time of the qualify-
ing acute coronary event (with the elevation 
related to percutaneous coronary intervention in 
2% of the patients), and 13% of the patients did 
not. The median time from the qualifying event 
to random assignment was 61 days. The baseline 
characteristics of the two study groups (assessed 
at the time of randomization) were well matched 
(Table 1). Most patients in the two groups were 
treated with aspirin, statins, thienopyridines, beta-
blockers, and angiotensin-converting–enzyme 
(ACE) inhibitors or angiotensin-receptor blockers 
(ARBs) and underwent a coronary revascular-
ization procedure between the time of the quali-
fying event and random assignment. The mean 
baseline LDL cholesterol level was 76 mg per 
deciliter (2.0 mmol per liter) (with a level of 
100 mg per deciliter or lower in 86% of the 
 patients), the mean HDL cholesterol level was 
42 mg per deciliter (1.1 mmol per liter), the mean 
apolipoprotein A1 level was 137 mg per deciliter, 
and the mean apolipoprotein B level was 81 mg 
per deciliter.
At the second prespecified interim analysis, 
which included 1135 primary end-point events 
(71% of those projected), the independent data 
and safety monitoring board recommended ter-
mination of the trial for futility, in accordance 
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with prespecified criteria (see the Supplementary 
Appendix). The sponsor and executive steering 
committee accepted this recommendation and 
terminated the trial; the median follow-up peri-
od was 31 months. Before termination of the 
study, the study drug had been discontinued in 
21% of the patients in the dalcetrapib group and 
in 19% of the patients in the placebo group for 
reasons other than death. During the time they 
were receiving the study drug, 89% of the pa-
tients in both groups had at least 80% adherence 
to the prescribed regimen. A total of 2.3% of the 
Table 1. Baseline Characteristics of the Patients.*
Characteristic
Placebo 
(N = 7933)
Dalcetrapib 
(N = 7938)
Age — yr 60.1±9.1 60.3±9.1
Female sex — no. (%) 1497 (19) 1573 (20)
Race — no. (%)†
White 7015 (88) 7008 (88)
Asian 602 (8) 630 (8)
Black 193 (2) 175 (2)
Other 123 (2) 125 (2)
Body-mass index‡ 28.6±5.1 28.6±5.0
Region of enrollment — no. (%)
Europe or Israel 3954 (50) 3959 (50)
North America 2521 (32) 2522 (32)
South America 639 (8) 639 (8)
Asia 526 (7) 524 (7)
Australia, New Zealand, or South Africa 293 (4) 294 (4)
Cardiovascular risk factors — no./total no. (%)
Hypertension 5419/7933 (68) 5336/7938 (67)
Diabetes 1952/7933 (25) 1930/7938 (24)
Hypercholesterolemia 5753/7933 (73) 5736/7938 (72)
Current smoker 1651/7933 (21) 1672/7938 (21)
Metabolic syndrome§ 4973/7914 (63) 4963/7920 (63)
Cardiovascular disease history — no. (%)
Myocardial infarction 1196 (15) 1276 (16)
PCI 1150 (14) 1159 (15)
CABG 462 (6) 432 (5)
Stroke 272 (3) 265 (3)
Peripheral arterial disease 583 (7) 568 (7)
NYHA class I or II congestive heart failure 1220 (15) 1233 (16)
Index diagnosis — no. (%)
Spontaneous myocardial infarction 6717 (85) 6745 (85)
STEMI 3611 (46) 3639 (46)
NSTEMI 3106 (39) 3105 (39)
Myocardial infarction related to PCI 149 (2) 174 (2)
Unstable angina without elevated biomarkers 1064 (13) 1019 (13)
PCI or CABG for index event 7222 (91) 7244 (91)
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patients in the dalcetrapib group and 2.0% of 
those in the placebo group withdrew consent, 
and an additional 1.6% and 1.3%, respectively, 
were lost to follow-up, with unknown final vital 
status.
Lipoproteins and Glycemic Control
Over the course of the trial, HDL cholesterol 
levels increased from baseline by 4 to 11% in 
the placebo group and by 31 to 40% in the dal-
cetrapib group. Dalcetrapib had a minimal ef-
fect on LDL cholesterol levels (Fig. 1). Triglycer-
ide levels increased from baseline by 6 to 17% in 
the placebo group and by 4 to 10% in the dalce-
trapib group (see the Supplementary Appendix). 
Apolipoprotein A1 levels were increased by 10% 
after 3 months of treatment with dalcetrapib 
and by 9% at the end of the trial (P<0.001), with 
a minimal effect on levels of apolipoprotein B. 
Treatment with dalcetrapib had no effect on 
fasting plasma glucose or glycated hemoglobin 
levels (see the Supplementary Appendix).
Table 1. (Continued.)
Characteristic
Placebo 
(N = 7933)
Dalcetrapib 
(N = 7938)
Time from index event to randomization — days
Mean 61 61
Range 16–184 18–181
Medications — no. (%)
Statin 7736 (98) 7722 (97)
Aspirin 7694 (97) 7705 (97)
Clopidogrel, ticlopidine, or prasugrel 7060 (89) 7071 (89)
Beta-blocker 6946 (88) 6931 (87)
ACE inhibitor or ARB 6271 (79) 6300 (79)
Lipids, lipoproteins, and apolipoproteins — mg/dl¶
LDL cholesterol 75.8±25.9 76.4±26.4
HDL cholesterol 42.2±11.5 42.5±11.7
Triglycerides 133.0±73.6 134.2±73.6
Apolipoprotein B 81.1±22.2 81.5±22.4
Apolipoprotein A1 137.2±24.2 137.5±24.4
Glycated hemoglobin — %‖ 6.0±0.86 6.0±0.86
Creatinine clearance <60 ml/min/1.73 m2 — no./total no. (%)** 854/7916 (11) 838/7915 (11)
C-reactive protein — mg/liter††
Median 1.5 1.5
Interquartile range 0.8–3.6 0.7–3.6
*  Plus–minus values are means ±SD. There was no significant difference between the groups in any baseline character-
istic. Additional information on baseline characteristics is contained in the Supplementary Appendix. To convert the 
values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles 
per liter, multiply by 0.01129. ACE denotes angiotensin-converting enzyme, ARB angiotensin-receptor blocker, CABG 
coronary-artery bypass grafting, NSTEMI non–ST-segment elevation myocardial infarction, NYHA New York Heart 
Association, PCI percutaneous coronary intervention, and STEMI ST-segment elevation myocardial infarction.
† Race was self-reported.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  The metabolic syndrome was defined according to the criteria of the International Diabetes Federation.
¶  Data on lipoprotein levels were available for 7907 patients in the placebo group and 7910 in the dalcetrapib group; 
data on apolipoprotein levels were available for 7734 patients in the placebo group and 7736 in the dalcetrapib group.
‖  Data on glycated hemoglobin levels were available for 7908 patients in the placebo group and 7911 in the dalcetrapib group.
**  Creatinine clearance was estimated with the use of the Cockcroft–Gault equation.
††  Data on C-reactive protein levels were available for 7469 patients in the placebo group and 7469 in the dalcetrapib group.
The New England Journal of Medicine 
Downloaded from nejm.org at GLASGOW UNIVERSITY LIBRARY on February 14, 2013. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 367;22 nejm.org november 29, 20122094
End Points
Dalcetrapib had no significant effect on the pri-
mary end point, which occurred in 8.3% of the 
patients in the dalcetrapib group and in 8.0% of 
the patients in the placebo group (hazard ratio 
with dalcetrapib, 1.04; 95% confidence interval, 
0.93 to 1.16; P = 0.52) (Fig. 2). Dalcetrapib also 
had no significant effect on the rate of any com-
ponent of the primary end point, on the rate of 
unanticipated coronary revascularization, or on 
the rate of death from any cause (Table 2). Pre-
specified subgroup analyses showed no signifi-
cant effect of dalcetrapib on the primary end 
point (see the Supplementary Appendix).
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Figure 1. Effects of the Study Drug on Mean High-Density Lipoprotein (HDL) Cholesterol and Low-Density Lipo-
protein (LDL) Cholesterol Levels.
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Association between Lipoprotein Levels  
and End Points
There was no significant association in either 
group between the baseline HDL cholesterol level 
(i.e., the level measured at randomization) and 
the risk of the primary end point, either in uni-
variate analysis or in multivariate analysis adjust-
ed for the factors listed in Figure 3A. There was 
no significant interaction between the baseline 
HDL cholesterol level and the group assignment 
with respect to the risk of the primary end point. 
In contrast, significant positive univariate rela-
tionships were identified in both treatment 
groups between the baseline values for LDL cho-
lesterol, very-low-density lipoprotein cholesterol, 
apolipoprotein B, glycated hemoglobin, high-
sensitivity C-reactive protein, and systolic blood 
pressure and the risk of the primary end point 
(see the Supplementary Appendix).
Although the distribution of HDL cholesterol 
levels was shifted as a result of dalcetrapib treat-
ment, there was no significant association in 
either group between the change in HDL choles-
terol levels from baseline to month 1 of the as-
signed regimen and the risk of the primary end 
point after month 1 (Fig. 3B). Associations were 
absent in a multivariate analysis that was ad-
justed for the characteristics listed in Figure 3A 
and for the changes from baseline to month 1 in 
systolic blood pressure and LDL cholesterol lev-
els. There was no significant interaction be-
tween the change in HDL cholesterol levels from 
baseline to month 1 and the group assignment 
with respect to the risk of the primary end point 
after month 1. Analysis of the association be-
tween the absolute level of HDL cholesterol at 
month 1 and the risk of the primary end point 
after month 1 showed similar findings (see the 
Supplementary Appendix).
There was no significant association in either 
group between the apolipoprotein A1 level mea-
sured at baseline and the risk of the primary end 
point or between the apolipoprotein A1 level 
measured at month 3 of the assigned regimen 
and the risk of the primary end point after 
month 3 (see the Supplementary Appendix).
C-Reactive Protein
At baseline, the median high-sensitivity C-reac-
tive protein level was similar in the two groups 
(1.5 mg per liter). Three months after random-
ization, the median C-reactive protein level was 
1.4 mg per liter in the placebo group and 1.6 mg 
per liter in the dalcetrapib group (a difference of 
18%, as calculated with the use of analysis of 
variance after log transformation; P<0.001).
Safety
Dalcetrapib had a generally acceptable side-effect 
profile. However, the mean systolic blood pres-
sure remained approximately 0.6 mm Hg higher 
in the dalcetrapib group than in the placebo 
group (P<0.001). There were no significant be-
tween-group differences in diastolic blood pres-
sure; pulse rate; levels of plasma aldosterone, 
potassium, or bicarbonate; or the number of pre-
scribed antihypertensive medications. Hyperten-
sion was reported more frequently as an adverse 
or serious adverse event in the dalcetrapib group 
than in the placebo group (see the Supplemen-
tary Appendix). Diarrhea occurred more fre-
quently in the dalcetrapib group than in the pla-
cebo group (in 563 patients vs. 358 patients), 
leading to discontinuation of the study drug in 
1.4% and 0.3% of the patients in the two groups, 
respectively. More patients in the dalcetrapib 
group than in the placebo group had insomnia 
(169 patients vs. 133 patients). There were no sig-
nificant differences between the groups in new 
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diagnoses of or deaths from cancers or infections 
(see the Supplementary Appendix). Dalcetrapib 
had no significant effect on measures of hepatic 
or renal function or on creatine kinase levels.
Discussion
The dal-OUTCOMES trial evaluated whether 
treatment with the CETP inhibitor dalcetrapib 
modified cardiovascular risk in patients who had 
had a recent acute coronary syndrome. Despite 
the finding that dalcetrapib, as compared with 
placebo, produced a substantial increase in HDL 
cholesterol levels, it had no significant effect on 
major cardiovascular outcomes, including the 
rate of death from coronary heart disease and the 
rates of myocardial infarction, ischemic stroke, 
unstable angina, cardiac arrest with resuscita-
tion, and unanticipated coronary revasculariza-
tion. No net benefit or harm was evident in any 
major subgroup of the study cohort. Because dal-
cetrapib had minimal effects on levels of LDL 
cholesterol and apolipoprotein B and a small ef-
fect on triglyceride levels, the dal-OUTCOMES 
trial may provide the purest test to date of the 
value of therapeutic intervention to raise HDL 
cholesterol levels in patients with coronary heart 
disease.
There are several possible explanations for 
the lack of benefit of dalcetrapib treatment. 
First, and in contrast to findings in epidemio-
logic analyses and post hoc analyses of data 
from some placebo-controlled trials of statins,2-7 
no association was shown between HDL choles-
terol levels and cardiovascular risk among the 
patients evaluated in this trial, even those in the 
placebo group. The absence of such an associa-
tion may indicate that HDL cholesterol levels are 
no longer a determinant of risk when patients 
are treated with the type of evidence-based 
therapies that were used in the trial, including 
statins, dual antiplatelet therapy, beta-blockers, 
ACE inhibitors or ARBs, and coronary revascu-
larization procedures. Another possibility is that 
HDLs are protective in healthy persons who do 
not have established cardiovascular disease but 
that their composition is altered in the presence 
of cardiovascular disease, rendering them non-
protective even at high levels or after therapeutic 
intervention. Specifically, the composition and 
function of HDLs might have been altered in an 
adverse fashion after the qualifying acute coro-
Table 2. Primary and Secondary End-Point Events.*
End Point
Placebo
(N = 7933)
Dalcetrapib
(N = 7938)
Hazard Ratio 
with Dalcetrapib 
(95% CI) P Value
Patients  
with Event
Event Rate  
at 3 Yr
Patients  
with Event
Event Rate  
at 3 Yr
no. (%) % (95% CI) no. (%) % (95% CI)
Primary end point 633 (8.0) 9.1 (8.4–9.9) 656 (8.3) 9.2 (8.5–9.9) 1.04 (0.93–1.16) 0.52
Death from coronary heart disease 125 (1.6) 1.8 (1.5–2.2) 118 (1.5) 1.6 (1.3–1.9) 0.94 (0.73–1.21) 0.66
Nonfatal acute myocardial infarction 407 (5.1) 6.0 (5.4–6.7) 414 (5.2) 5.9 (5.3–6.5) 1.02 (0.89–1.17) 0.80
Hospitalization for unstable angina 
with objective evidence of acute 
myocardial ischemia
92 (1.2) 1.3 (1.0–1.5) 84 (1.1) 1.3 (1.0–1.6) 0.91 (0.68–1.22) 0.54
Cardiac arrest with resuscitation 10 (0.1) 0.1 (0.0–0.2) 14 (0.2) 0.2 (0.1–0.3) 1.41 (0.63–3.18) 0.40
Stroke of presumed atherothrom-
botic cause
73 (0.9) 1.0 (0.8–1.2) 91 (1.1) 1.4 (1.1–1.7) 1.25 (0.92–1.70) 0.16
Death from any cause 229 (2.9) 3.4 (2.9–3.9) 226 (2.8) 3.1 (2.7–3.6) 0.99 (0.82–1.19) 0.90
Unanticipated coronary revasculariza-
tion procedure†
672 (8.5)  9.6 (8.9–10.3) 674 (8.5)  9.5 (8.8–10.3) 1.00 (0.90–1.11) 0.97
* The primary efficacy end point was a composite of death from coronary heart disease, major nonfatal coronary events (acute myocardial in-
farction, hospitalization for unstable angina with objective evidence of acute myocardial ischemia, or cardiac arrest with resuscitation), or 
stroke of presumed atherothrombotic cause. Secondary efficacy end-point events included each component of the primary composite end 
point, unanticipated coronary revascularization (not including revascularization for restenosis at the previous intervention site), and death 
from any cause. Event rates are Kaplan–Meier estimates through 36 months.
† Data are for procedures other than those for restenosis at the previous intervention site.
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nary event, owing to the acute-phase response 
that occurs in the wake of myocardial infarc-
tion.26,27 However, other manifestations of 
acute-phase response after myocardial infarction 
wane before 61 days,28 which was the median 
time from the index event to the time of random 
assignment in this trial. Moreover, we observed 
neither an early harm nor a later benefit of treat-
ment but rather a neutral effect of treatment 
throughout an observation period of up to 3 years, 
well into the chronic phase of coronary heart 
disease. Therefore, it is unlikely that dalcetrapib 
would have shown a benefit after an even longer 
period of follow-up. Finally, measurements of 
HDL cholesterol levels may not reflect the physi-
ologic functions of HDLs, including reverse 
cholesterol transport.29 It remains unknown 
whether dalcetrapib affected the function of 
HDLs in this study.
It is also possible that favorable effects of 
dalcetrapib with respect to HDL cholesterol were 
offset by other, unfavorable effects of treatment. 
The mean increase of 0.6 mm Hg in systolic 
blood pressure with dalcetrapib is unlikely to 
have had major direct clinical consequences30
but might indicate other underlying adverse vas-
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Dalcetrapib PlaceboFigure 3. Association between HDL Cholesterol Level 
and Risk of the Primary End Point.
Panel A shows the annualized risk of the primary end 
point according to quintile of HDL cholesterol level at 
baseline (quintile 1, ≤33 mg per deciliter; quintile 2, >33 
to 38 mg per deciliter; quintile 3, >38 to 43 mg per deci-
liter; quintile 4, >43 to 51 mg per deciliter; and quintile 5, 
>51 mg per deciliter). Panel B shows the annualized risk 
of the primary end point beginning 1 month after ran-
domization according to quintiles of change in HDL 
cholesterol levels from baseline to 1 month after ran-
domization (quintiles of change for dalcetrapib, ≤5 mg 
per deciliter, >5 to 9 mg per deciliter, >9 to 14 mg per 
deciliter, >14 to 20 mg per deciliter, and >20 mg per 
deciliter; quintiles of change for placebo, −3 mg per 
deciliter or less, greater than −3 to 0 mg per deciliter, 
>0 to 2 mg per deciliter, >2 to 5 mg per deciliter, and 
>5 mg per deciliter). The position of each quintile of 
HDL cholesterol on the x axis corresponds to the me-
dian value of HDL cholesterol within that quintile. (In 
Panel A, the data positions on the x axis for the two 
treatment groups are offset from the common median 
by 0.30 mg per deciliter to avoid overlap.) Data for rates 
are plotted as point estimates with 95% confidence in-
tervals. Associations in Panels A and B have been ad-
justed for age; sex; geographic region; body-mass in-
dex; waist-to-hip ratio; status with respect to a history 
of diabetes, hypercholesterolemia, hypertension, meta-
bolic syndrome, previous myocardial infarction, un-
stable angina, or percutaneous coronary intervention; 
smoking status at the time of randomization; presence 
or absence of impaired glomerular filtration rate (<60 ml 
per minute per 1.73 m2); and baseline LDL cholesterol 
level. Associations in Panel B have been additionally 
adjusted for the change from baseline to month 1 in 
systolic blood pressure, LDL cholesterol level, and C- 
reactive protein level. In Panel A, there was no signifi-
cant main effect of HDL cholesterol on the risk of the 
primary end point in either the dal cetrapib group or 
the placebo group (P = 0.77 for both comparisons). There 
was no significant interaction between group assign-
ment and baseline HDL cholesterol level with respect 
to the risk of the primary end point (P = 0.94). In Panel B, 
there was no significant main effect of the change in 
HDL cholesterol level from baseline to month 1 with 
respect to the risk of the primary end point after 
month 1 in either the dalcetrapib group (P = 0.23) or 
the placebo group (P = 0.62). There was no significant 
interaction between group assignment and change in 
HDL cholesterol level from baseline to month 1 with 
respect to the risk of the primary end point after 
month 1 (P = 0.15).
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cular effects. Similarly, the 18% increase in the 
median C-reactive protein level with dalcetrapib 
might indicate a proinflammatory effect of treat-
ment associated with a greater risk of cardiovas-
cular events.8 Modest but significant increases 
in blood pressure or C-reactive protein levels 
have also been observed in patients with or at 
high risk for coronary heart disease who were 
treated with torcetrapib or anacetrapib.22,31 Since 
the structure of dalcetrapib is dissimilar to that 
of the other two agents,32 the composite find-
ings may indicate adverse effects of CETP inhibi-
tion, rather than specific off-target effects of 
individual agents.
It is unlikely that a clinically meaningful ben-
efit of dalcetrapib went undetected owing to a 
type 2 statistical error. On the basis of the re-
sults observed for the primary efficacy measure, 
there is only a 1.1% likelihood of a true risk re-
duction of 10% or more. Moreover, dalcetrapib 
had concordantly neutral effects on all compo-
nents of the primary end point and on the rate 
of coronary revascularization.
In summary, the addition of dalcetrapib to 
standard therapy after an acute coronary syn-
drome raised the levels of HDL cholesterol and 
apolipoprotein A1 and had minimal effects on 
levels of LDL cholesterol and apolipoprotein B. 
In addition, triglyceride levels increased less in 
the dalcetrapib group than in the placebo group. 
The risk of major cardiovascular outcomes was 
not significantly altered. It remains possible that 
agents that inhibit CETP and raise HDL choles-
terol levels to a greater degree than did dalcetra-
pib and that also lower LDL cholesterol lev-
els31,33 will prove to have clinical effects different 
from those of dalcetrapib.
Supported by F. Hoffmann–La Roche.
Dr. Schwartz reports receiving grant support on behalf of his 
institution from Anthera Pharmaceuticals, Resverlogix, Roche, 
and Sanofi; Dr. Olsson, receiving lecture fees from AstraZeneca 
and serving on an advisory board for Karo Bio and Merck; Drs. 
Abt, Kallend, Brumm, and Mundl, being employees of Roche; 
Dr. Ballantyne, receiving consulting fees from Abbott, Adnexus, 
Amarin, Amylin, AstraZeneca, Bristol-Myers Squibb, Esperion 
Therapeutics, Genentech, GlaxoSmithKline, Idera Pharmaceuti-
cals, Kowa Pharmaceuticals, Merck, Novartis, Omthera Pharma-
ceuticals, Pfizer, Resverlogix, Roche, Sanofi, and Takeda Pharma-
ceuticals, lecture fees from Abbott, GlaxoSmithKline, and Merck, 
and grant support on behalf of his institution from Abbott, 
Amarin, AstraZeneca, Bristol-Myers Squibb, Genentech, Glaxo-
SmithKline, Kowa Pharmaceuticals, Merck, Novartis, Sanofi, 
and Takeda Pharmaceuticals; Dr. Barter, receiving consulting 
fees from CSL Behring and Merck, lecture fees from AstraZeneca, 
Kowa Pharmaceuticals, Merck, Pfizer, and Roche, and reimburse-
ment for travel expenses from AstraZeneca, CSL Behring, Merck, 
and Pfizer; Dr. Chaitman, receiving consulting fees from Merck, 
Pfizer, and Abbott; Dr. Leiter, receiving consulting fees from 
Abbott, Amgen, AstraZeneca, Eli Lilly, Merck, Roche, and Sanofi, 
lecture fees from AstraZeneca, Eli Lilly, Merck, and Roche, fees 
for development of educational materials from Merck, and grant 
support on behalf of his institution from Amgen, AstraZeneca, 
Eli Lilly, Merck, Roche, and Sanofi; Dr. Leitersdorf, serving on a 
board for and receiving consulting fees from Novartis and Merck, 
receiving lecture fees from Merck, and receiving grant support 
on behalf of his institution from Merck; Dr. McMurray, receiving 
reimbursement for travel expenses from Roche and consulting 
fees on behalf of his institution from Roche; Dr. Nicholls, receiv-
ing consulting fees from Boehringer Ingelheim, CSL Behring, 
Merck, Omthera Pharmaceuticals, Roche, and Takeda Pharma-
ceuticals and grant support on behalf of his institution from 
Anthera Pharmaceuticals, AstraZeneca, Eli Lilly, Novartis, Resver-
logix, and Roche; Dr. Shah, receiving consulting fees from 
Roche; Dr. Tardif, receiving lecture fees from Roche and Servier 
and grant support on behalf of his institution from Cerenis 
Therapeutics, Merck, Roche, and Servier; and Dr. Wright, receiv-
ing fees for the development of educational presentations from 
Vindico Medical Education and consulting fees from Roche for 
himself and on behalf of his institution. No other potential 
conflict of interest relevant to this article was reported.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank the patients who participated in this trial, the study 
coordinators, and the investigators (see the Supplementary Ap-
pendix) at all 935 study sites.
References
1. Barter P. Metabolic abnormalities: 
high-density lipoproteins. Endocrinol 
Metab Clin North Am 2004;33:393-403.
2. Assmann G, Schulte H. Relation of 
high-density lipoprotein cholesterol and 
triglycerides to incidence of atherosclerotic 
coronary artery disease (the PROCAM ex-
perience). Am J Cardiol 1992;70:733-7.
3. Gordon T, Castelli WP, Hjortland MC, 
Kannel WB, Dawber TR. High density lipo-
protein as a protective factor against coro-
nary heart disease: the Framingham Study. 
Am J Med 1977;62:707-14.
4. Baseline serum cholesterol and treat-
ment effect in the Scandinavian Simvas-
tatin Survival Study (4S). Lancet 1995;345: 
1274-5.
5. Heart Protection Study Collaborative 
Group. MRC/BHF Heart Protection Study 
of cholesterol lowering with simvastatin 
in 20,536 high-risk individuals: a random-
ised placebo-controlled trial. Lancet 2002; 
360:7-22.
6. Baigent C, Keech A, Kearney PM, et al. 
Efficacy and safety of cholesterol-lower-
ing treatment: prospective meta-analysis 
of data from 90,056 participants in 14 ran-
domised trials of statins. Lancet 2005;366: 
1267-78. [Errata, Lancet 2005;366:1358, 
2008;371:2084.]
7. Olsson AG, Schwartz GG, Szarek M, 
et al. High-density lipoprotein, but not 
low-density lipoprotein cholesterol levels 
influence short-term prognosis after acute 
coronary syndrome: results from the 
MIRACL trial. Eur Heart J 2005;26:890-6.
8. Ray KK, Cannon CP, Cairns R, Mor-
row DA, Ridker PM, Braunwald E. Prog-
nostic utility of apoB/AI, total cholesterol/
HDL, non-HDL cholesterol, or hs-CRP as 
predictors of clinical risk in patients re-
ceiving statin therapy after acute coronary 
syndromes: results from PROVE IT-TIMI 
22. Arterioscler Thromb Vasc Biol 2009; 
29:424-30.
9. Mora S, Glynn RJ, Boekholdt SM, 
 Nordestgaard BG, Kastelein JJ, Ridker PM. 
On-treatment non-high-density lipopro-
tein cholesterol, apolipoprotein B, triglyc-
erides, and lipid ratios in relation to re-
sidual vascular risk after treatment with 
The New England Journal of Medicine 
Downloaded from nejm.org at GLASGOW UNIVERSITY LIBRARY on February 14, 2013. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
Dalcetr apib and recent acute Coronary Syndrome
n engl j med 367;22 nejm.org november 29, 2012 2099
potent statin therapy: JUPITER (Justifica-
tion for the Use of Statins in Prevention: 
an Intervention Trial Evaluating Rosuvas-
tatin). J Am Coll Cardiol 2012;59:1521-8.
10. Wolfram RM, Brewer HB, Xue Z, et al. 
Impact of low high-density lipoproteins 
on in-hospital events and one-year clini-
cal outcomes in patients with non-ST-ele-
vation myocardial infarction acute coro-
nary syndrome treated with drug-eluting 
stent implantation. Am J Cardiol 2006;98: 
711-7.
11. Rubins HB, Robins SJ, Collins D, et al. 
Gemfibrozil for the secondary prevention 
of coronary heart disease in men with low 
levels of high-density lipoprotein choles-
terol. N Engl J Med 1999;341:410-8.
12. Frick MH, Elo O, Haapa K, et al. Hel-
sinki Heart Study: primary-prevention 
trial with gemfibrozil in middle-aged men 
with dyslipidemia. N Engl J Med 1987;317: 
1237-45.
13. The ACCORD Study Group. Effects of 
combination lipid therapy in type 2 diabe-
tes mellitus. N Engl J Med 2010;362:1563-
74. [Erratum, N Engl J Med 2010;362:1748.]
14. Keech A, Simes RJ, Barter P, et al. Ef-
fects of long-term fenofibrate therapy on 
cardiovascular events in 9795 people with 
type 2 diabetes mellitus (the FIELD study): 
randomised controlled trial. Lancet 2005; 
366:1849-61. [Errata, Lancet 2006;368: 
1415, 1420.]
15. The BIP Study Group. Secondary pre-
vention by raising HDL cholesterol and 
reducing triglycerides in patients with 
coronary artery disease: the Bezafibrate 
Infarction Prevention (BIP) study. Circula-
tion 2000;102:21-7.
16. The AIM-HIGH Investigators. Niacin 
in patients with low HDL cholesterol levels 
receiving intensive statin therapy. N Engl 
J Med 2011;365:2255-67. [Erratum, N Engl 
J Med 2012;367:189.]
17. Rosenson RS, Brewer HB Jr, Davidson 
WS, et al. Cholesterol efflux and athero-
protection: advancing the concept of re-
verse cholesterol transport. Circulation 
2012;125:1905-19.
18. Ridker PM, Paré G, Parker AN, Zee 
RY, Miletich JP, Chasman DI. Polymor-
phism in the CETP gene region, HDL cho-
lesterol, and risk of future myocardial 
infarction: genomewide analysis among 
18 245 initially healthy women from the 
Women’s Genome Health Study. Circ Car-
diovasc Genet 2009;2:26-33.
19. Thompson A, Di Angelantonio E, Sar-
war N, et al. Association of cholesteryl 
ester transfer protein genotypes with 
CETP mass and activity, lipid levels, and 
coronary risk. JAMA 2008;299:2777-88.
20. Voight BF, Peloso GM, Orho-Melander 
M, et al. Plasma HDL cholesterol and risk 
of myocardial infarction: a mendelian 
randomisation study. Lancet 2012;380: 
572-80. [Erratum, Lancet 2012;380:564.]
21. Zhong S, Sharp DS, Grove JS, et al. 
Increased coronary heart disease in Japa-
nese-American men with mutation in the 
cholesteryl ester transfer protein gene de-
spite increased HDL levels. J Clin Invest 
1996;97:2917-23.
22. Barter PJ, Caulfield M, Eriksson M, 
et al. Effects of torcetrapib in patients at 
high risk for coronary events. N Engl J 
Med 2007;357:2109-22.
23. Lüscher TF, Taddei S, Kaski JC, et al. 
Vascular effects and safety of dalcetrapib 
in patients with or at risk of coronary 
heart disease: the dal-VESSEL randomized 
clinical trial. Eur Heart J 2012;33:857-65.
24. Stein EA, Stroes ES, Steiner G, et al. 
Safety and tolerability of dalcetrapib. Am 
J Cardiol 2009;104:82-91.
25. Schwartz GG, Olsson AG, Ballantyne 
CM, et al. Rationale and design of the dal-
OUTCOMES trial: efficacy and safety of 
dalcetrapib in patients with recent acute 
coronary syndrome. Am Heart J 2009; 
158:896-901.
26. Navab M, Reddy ST, Van Lenten BJ, 
Fogelman AM. HDL and cardiovascular 
disease: atherogenic and atheroprotective 
mechanisms. Nat Rev Cardiol 2011;8:222-
32.
27. Besler C, Heinrich K, Rohrer L, et al. 
Mechanisms underlying adverse effects of 
HDL on eNOS-activating pathways in pa-
tients with coronary artery disease. J Clin 
Invest 2011;121:2693-708.
28. Rosenson RS. Myocardial injury: the 
acute phase response and lipoprotein me-
tabolism. J Am Coll Cardiol 1993;22:933-
40.
29. Khera AV, Cuchel M, de la Llera-Moya 
M, et al. Cholesterol efflux capacity, high-
density lipoprotein function, and athero-
sclerosis. N Engl J Med 2011;364:127-35.
30. Bangalore S, Qin J, Sloan S, Murphy 
SA, Cannon CP. What is the optimal 
blood pressure in patients after acute 
coronary syndromes?: Relationship of 
blood pressure and cardiovascular events 
in the PRavastatin OR atorVastatin Evalu-
ation and Infection Therapy-Thrombolysis 
In Myocardial Infarction (PROVE IT-TIMI) 
22 trial. Circulation 2010;122:2142-51.
31. Cannon CP, Shah S, Dansky HM, et al. 
Safety of anacetrapib in patients with or 
at high risk for coronary heart disease. 
N Engl J Med 2010;363:2406-15.
32. Schwartz GG. New horizons for cho-
lesterol ester transfer protein inhibitors. 
Curr Atheroscler Rep 2012;14:41-8.
33. Nicholls SJ, Brewer HB, Kastelein JJ, 
et al. Effects of the CETP inhibitor eva-
cetrapib administered as monotherapy or 
in combination with statins on HDL and 
LDL cholesterol: a randomized controlled 
trial. JAMA 2011;306:2099-109.
Copyright © 2012 Massachusetts Medical Society.
receive immediate notification when an article  
is published online first
To be notified by e-mail when Journal articles 
are published Online First, sign up at NEJM.org.
The New England Journal of Medicine 
Downloaded from nejm.org at GLASGOW UNIVERSITY LIBRARY on February 14, 2013. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
